A Study of LY3819253 in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff

A Study of LY3819253 in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff

Publication date: Aug 04, 2020

The purpose of this study is to evaluate whether LY3819253 prevents severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease – 2019 (COVID-19) in facility staff and residents in skilled nursing and assisted living facilities with a high risk of SARS-CoV-2 exposure. Participants with a high risk of SARS-CoV-2 exposure will receive LY3819253 or placebo via an injection into a vein. Samples will be taken from the nose. Blood samples will be drawn. Participation could last up to 25 weeks and may include up to 19 visits.

Concepts Keywords
Assisted Living Infection
Assisted Living Facilities SARS
BLAZE Intravenous infusions
Blood Sarbecovirus
Contraceptive Respiratory diseases
Coronavirus Animal diseases
Eli Lilly Zoonoses
Infection COVID-19
Informed Consent Coronavirus disease
Intravenous Draft:SARS-CoV-1
Monoclonal Antibodies Wuhan flu
Nasal Antibodies
Nasopharyngeal
Nursing
Oropharyngeal
Placebo
Plasma
Randomization
SARS
Serology
Systemic Disease
Turbinate
Vaccine
Venous Blood

Semantics

Type Source Name
disease MESH Infection
drug DRUGBANK Etoperidone
drug DRUGBANK Aspartame
disease MESH men
disease VO pregnant women
disease VO vaccine
disease VO company

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *